中文

iRhythm (IRTC)

Healthcare

Close on Nov 6, 2026 (from our latest article): $90.22

Market value
$3.0Bat the Nov 6 close
Revenue growth
+22%12 months to Sep 30, 2026 (10-Q)
FCF margin
1%12 months to Sep 30, 2026 (10-Q)
Net debt
$91Mat Sep 30, 2026
Worst fall since listing
−84.4%Jan 20, 2021 to Aug 19, 2021; not back to that high (−64.9% now)

About the company

Latest

  • Down 30.7% Move
    iRhythm falls 31% as FDA filing slips and its raise leans on an acquisition

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for iRhythm, FY2014–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $22M in FY2014 to $747M in FY2025. Free cash flow was positive in 1 of the 12 years shown; FY2025: $35M. Each year's figures are in the table below. −$200M$0$200M$400M$600M$800M ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $22M in FY2014 to $747M in FY2025.

Free cash flow was positive in 1 of the 12 years shown; FY2025: $35M.

Margins

Operating margin was −8% in FY2025, vs −16% in FY2020. Gross margin was 71% in FY2025, vs 73% in FY2020. Each year's figures are in the table below. −100%−50%0%50%100% ’15’17’19’21’23’25

Operating margin was −8% in FY2025, vs −16% in FY2020.

Gross margin was 71% in FY2025, vs 73% in FY2020.

Diluted share count

The diluted share count rose 15% from FY2020 to FY2025, to 32M. Each year's figures are in the table below. 24M26M28M30M32M34M ’19’20’21’22’23’24’25

The diluted share count rose 15% from FY2020 to FY2025, to 32M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$747M71%−8%−$45M$81M$46M$35M
FY2024$592M69%−20%−$113M$3M$34M−$31M
FY2023$493M67%−25%−$123M−$50M$40M−$91M
FY2022$411M69%−28%−$116M−$23M$30M−$53M
FY2021$323M66%−31%−$101M−$38M$28M−$66M
FY2020$265M73%−16%−$44M−$14M$14M−$27M
FY2019$215M76%−26%−$55M−$22M$20M−$42M
FY2018$147M74%−31%−$50M−$29M$5M−$34M
FY2017$99M72%−28%−$30M−$15M$4M−$18M
FY2016$64M67%−24%−$21M−$17M$3M−$19M
FY2015$36M59%−60%−$23M−$18M$2M−$20M
FY2014$22M51%−68%−$16M−$16M$0.5M−$16M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202532M$584M$650M$88M—$0
FY202431M$536M$646M$76M—$25M
FY202331M$134M$35M$77M—$0
FY202230M$213M$35M$58M—$0
FY202129M$239M$10M$55M——
FY202028M$335M$21M$42M——
FY201925M$149M$33M$26M——
FY2018—$78M$35M$16M——
FY2017—$105M$45M$10M——
FY2016—$106M$46M$2M——
FY2015—$25M$31M$1M——
FY2014—$9M—$0.8M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 6, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearIRTCS&P 500
2019−2.0%+31.5%
2020+248.4%+18.4%
2021−50.4%+28.7%
2022−20.4%−18.1%
2023+14.3%+26.3%
2024−15.8%+25.0%
2025+96.8%+17.9%
2026 to date−46.9%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Healthcare

Questions about iRhythm

Why did iRhythm stock fall on Nov 6, 2026?
iRhythm raised its 2026 revenue outlook, but only because of an acquisition; without it, the range is about 1% lower than in August. It also delayed the FDA filing for its next heart-monitoring patch to 2027 and said revenue from its Zio AT patch stopped growing. The shares fell about 31%, on a day the S&P 500 rose. Those changes are real, but no source we found explains a fall this large on their own. Read the article →